News Related to Pneumococcal Conjugate Vaccine

Related coverage linked through entity extraction aliases.

Vaxcyte Launches VAX-31 Phase 3 Program, Targets Adult BLA Filing by End of 2027

Feb 15, 2026

Vaxcyte has initiated its Phase 3 adult program for VAX-31, a 31-valent pneumococcal conjugate vaccine, with the pivotal OPUS-1 trial enrolling 4,000 adults aged 50 and older. The company plans to submit a Biologics License Application by the end of next year.

Merck Stock Surges 46% to 52-Week High on Post-Keytruda Pipeline Strength

Feb 13, 2026

Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.